Up to now, the duration of IM treatment before surgery is controversial without international consensus.[18] The resistance to imatinib of GIST always occurs 2 years after treatment because of the secondary mutation of PDGFRA. The gene discussed is PDGFRA; the disease is gastrointestinal stromal tumor.